玻璃体腔注射血管内皮生长因子抑制剂后眼内炎:管理与视力结局
该回顾性单中心非随机干预研究纳入2006至2016年玻璃体腔注射抗VEGF药物后发生眼内炎的40例患者,比较初始玻璃体穿刺注药(TAI)与平坦部玻璃体切除术(PPV)的6个月视力结局,发现两组间无显著差异,而就诊时年龄<85岁和眼压≤25 mmHg与更好视力结局相关。
要点
- 40例眼内炎中34例(85.0%)有疼痛、25例(62.5%)有前房积脓。
- 24例培养阳性中66.7%为凝固酶阴性葡萄球菌,10.0%为链球菌属。
- TAI组与PPV组6个月最佳矫正视力无显著差异。
核心结论
- TAI组与PPV组在6个月随访时最佳矫正视力无显著差异。
- 就诊时年龄<85岁和眼压≤25 mmHg与6个月随访时更好视力结局相关。
研究设计与样本
- 回顾性、单中心、非随机干预研究,纳入2006至2016年间玻璃体腔注射抗VEGF药物后发生眼内炎的患者。
- 所有患者在开始治疗前均行玻璃体活检送培养,分为TAI组与PPV联合玻璃体腔注射抗生素(PPV组)。
- 共258357次玻璃体腔注射中40例(0.016%)在注射后3周内发生眼内炎。
主要发现
- 34例(85.0%)初诊时有疼痛,25例(62.5%)有前房积脓。
- 24例培养阳性病例中,66.7%为凝固酶阴性葡萄球菌,10.0%为链球菌属。
- 链球菌属培养阳性者6个月BCVA(logMAR)为4.0(SD 0.8)(约光感),显著差于凝固酶阴性葡萄球菌阳性者的0.4(SD 0.3)(约20/50)(P < 0.0001)。
- PPV组培养阳性比例高于TAI组(90.9% vs 48.3%,P = 0.03)。
- TAI组与PPV组6个月BCVA无统计学显著差异。
关键数值与推荐
- 链球菌属培养阳性者6个月BCVA(logMAR)4.0(SD 0.8)vs 凝固酶阴性葡萄球菌阳性者0.4(SD 0.3),P < 0.0001。
- PPV组培养阳性率90.9% vs TAI组48.3%,P = 0.03。
- 就诊时年龄<85岁和眼压≤25 mmHg为6个月BCVA达20/400或更好的预测因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We describe the presentation of patients developing endophthalmitis after intravitreal injection with vascular endothelial growth factor (VEGF) inhibitors. Moreover, we evaluate the management by comparing the outcomes of immediate tap and injection of intravitreal antibiotics (TAI) versus initial surgical pars plana vitrectomy (PPV). Finally, we analyze the predictive factors of visual outcomes at 6-month follow-up. DESIGN: Retrospective, single-center, nonrandomized interventional study. PARTICIPANTS: Patients developing endophthalmitis after receiving an intravitreal injection of anti-VEGF agent between 2006 and 2016. METHODS: All patients received a vitreous biopsy sent for cultures before the initiation of treatment: TAI group versus PPV with intravitreal antibiotics (PPV group). MAIN OUTCOME MEASURES: Best-corrected visual acuity (BCVA) at 6-month follow-up after treatment for endophthalmitis. RESULTS: A total of 258 357 intravitreal injections occurred over the course of the 10-year period, of which 40 patients (0.016%) had endophthalmitis within 3 weeks after injection. In total, 34 patients (85.0%) had pain and 25 patients (62.5%) had hypopyon on initial examination. Among 24 culture-positive cases, 66.7% of the causative organisms were coagulase-negative Staphylococcus, followed by Streptococcus species (10.0%). The best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution [logMAR]) at 6-month follow-up was significantly worse for patients who had a positive culture for Streptococcus species (4.0; standard deviation [SD], 0.8) (approximately light perception) compared with those who had a positive culture for coagulase-negative Staphylococcus (0.4; SD, 0.3) (∼20/50) (P < 0.0001). Compared with the TAI group, a higher proportion of samples were culture-positive in the PPV group (90.9% vs. 48.3%, P = 0.03). There was no statistically significant difference in BCVA at 6-month follow-up between the TAI and PPV groups. Younger age (<85 years) and lower intraocular pressure (IOP) (≤25 mmHg) at presentation were predictive of achieving a BCVA of 20/400 or better at 6-month follow-up after treatment. Initial management (TAI vs. PPV), duration of symptoms, presence of pain, presence of hypopyon, presenting BCVA, and culture status (positive vs. negative) were not found to be predictive of visual outcomes at 6-month follow-up. CONCLUSIONS: No significant difference in BCVA at 6-month follow-up was detected between the TAI and PPV groups. Younger age and lower IOP at presentation were associated with better visual outcomes at 6-month follow-up.
引用
- Xu K, Chin EK, Bennett SR, et al. Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes. Ophthalmology. 2018. PMID: 29477689. doi:10.1016/j.ophtha.2018.01.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。